FOLH1 and prostate carcinoma: There are currently two FDA approved PSMA PET radiopharmaceuticals for patients with suspected prostate cancer metastasis who are candidates for initial definitive therapy or suspected recurrence based on elevated PSA levels: 68Ga PSMA-11 (Ga 68 gozezotide, Illuccix®, Locametz®) and 18F DCFPyL (Pifluofolastat F 18, Pylarify®).